Interleukin-2-associated bullous drug dermatosis

Dermatology

Volumn 210, Issue 1, 2005, Pages 74-75

  Hofmann, M ^a,b   Audring, H ^a   Sterry, W ^a   Trefzer, U ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Bullous drug dermatosis; Interleukin 2 associated dermatosis; Metastatic melanoma

Indexed keywords

DACARBAZINE; INTERLEUKIN 2; METHOTREXATE;

AGED; ANAMNESIS; ARTICLE; BONE METASTASIS; BULLOUS SKIN DISEASE; CASE REPORT; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOTHERAPY; MALE; MELANOMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN BIOPSY; THYROID CANCER;

AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; HUMANS; INTERLEUKIN-2; MALE; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS; THYROID NEOPLASMS;

EID: 10644285450     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081491     Document Type: Article

References (20)

1. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
2. Ruocco V, Sacerdoti G: Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol 1991;30:307-312.
3. Fellner MJ: Drug-induced bullous pemphigoid. Clin Dermatol 1993;11:515-520.
4. Asnis LA, Gaspari AA: Cutaneous reactions to recombinant cytokine therapy. Am Acad Dermatol 1995;33:393-410.
5. Trefzer U, Hofmann M, Sterry W: Kutane Nebenwirkungen klinisch relevanter Zytokintherapien. Dtsch Med Wochenschr 2003;128:1782-1779.
6. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474-485.
7. Malaguarnera M, Ferlito L, Gulizia G, Di Fazio I, Pistone G: Use of interleukin-2 in advanced renal carcinoma: Meta-analysis and review of the literature. Eur J Clin Pharmacol 2001;57:267-273.
8. Wolkenstein P, Chosidow O, Wechsler J, Guillaume JC, Lescs MC, Brandely M, Avril MF, Revuz J: Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol 1993;28:66-70.
9. Ramseur WL, Richards F 2nd, Duggan DB: A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy. Cancer 1989;63:2005-2007.
10. Prussick R, Plott RT, Stanley JR: Recurrence of pemphigus vulgaris associated with interleukin 2 therapy. Arch Dermatol 1994;130:890-893.
11. Tranvan A, Pezen DS, Medenica M, Michelson GC, Vogelzang N, Soltani KM: Interleukin-2 associated linear IgA bullous dermatosis. J Am Acad Dermatol 1996;35:865-867.
12. Guillaume JC, Escudier B, Espagne E, Roujeau JC, Prost C, Domart P, Nitenberg G, Avril MF: Bullous dermatosis with linear IgA deposits along the basement membrane during treatment with gamma interferon and interleukin-2. Ann Dermatol Vénéréol 1990;117:899-902.
13. Wiener JS, Tucker JA Jr, Walther PJ: Interleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysis. South Med J 1992;85:656-659.
14. Staunton MR, Scully MC, Le Boit PE, Aronson FR: Life-threatening bullous skin eruptions during interleukin-2 therapy. J Natl Cancer Inst 1991;83:56-57.
15. Buzaid AC, Atkins M: Practical guidelines for the management of biochemotherapy-related toxicity in melanoma. Clin Cancer Res 2001;7:2611-2619.
16. Villada G, Roujeau JC, Clerici T, Bourgault I, Revuz J: Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: An immunopathologic study of five cases. Arch Dermatol 1992;128:50-53.
17. Correia O, Delgado L, Roujeau JC, Le Cleach L, Fleming-Torrinha JA: Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: A comparative analysis of serum and blister fluid samples. Arch Dermatol 2002;138:29-32.
18. Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Pierard GE: Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol 2000;22:413-417.
19. Gaspari AA: Autoimmunity as a complication of interleukin 2 immunotherapy: Many unanswered questions. Arch Dermatol 1994;130:894-898.
20. Cotran RS, Pober JS, Gimbrone MA Jr, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT: Endothelial activation during interleukin 2 immunotherapy: A possible mechanism for the vascular leak syndrome. J Immunol 1988;140:1883-1888.